While Herceptin is being used as a first-line drug treatment for HER2-positive breast cancer, about 52% of breast cancer patients fail to respond to the initial Herceptin treatment or develop resistance to the antibody therapy within one year (9–11). The gene discussed is ERBB2; the disease is breast carcinoma.